8-K: Collegium Pharmaceutical Reports Record Fourth Quarter and Full-Year 2024 Results, Reaffirms 2025 Guidance

Collegium Pharmaceutical announces record financial results for Q4 and full-year 2024, driven by strong performance in its pain portfolio and the addition of Jornay PM, and reaffirms its full-year 2025 guidance.

Summary

• Collegium Pharmaceutical reported record net revenue of $181.9 million for the fourth quarter and $631.4 million for the full year 2024.
• The company achieved GAAP net income of $12.5 million for the quarter and $69.2 million for the year.
• Adjusted EBITDA reached a record $107.7 million for the quarter and $401.2 million for the year.
• Jornay PM net revenue was $29.3 million for the quarter and pro forma net revenue was $100.7 million for the year.
• The company ended 2024 with $162.8 million in cash, cash equivalents, and marketable securities.
• Collegium repurchased $60.0 million in shares during 2024.
• The company reaffirmed its full-year 2025 guidance, projecting net product revenues between $735.0 and $750.0 million and adjusted EBITDA between $435.0 and $450.0 million.
• The company expects Jornay PM net revenue to exceed $135 million in 2025.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record financial results, reaffirmed guidance, and strategic growth initiatives. The company's strong cash position and focus on shareholder value further contribute to the positive sentiment.

Positives

• Record quarterly and full-year net revenue were achieved.
• Jornay PM is experiencing strong growth and is expected to exceed $135 million in net revenue in 2025.
• Belbuca and Xtampza ER also achieved record net revenue in Q4 2024.
• The company is strategically deploying capital, including share repurchases and debt repayment.
• Collegium has a strong cash position and low net debt to adjusted EBITDA ratio.
• The company is expanding into neuropsychiatry with the acquisition of Ironshore Therapeutics.
• The company is focused on growing Jornay PM, maximizing its pain portfolio, and strategically deploying capital to create value.

Negatives

• GAAP operating expenses increased significantly year-over-year, up 83% for the quarter and 30% for the full year.
• Cash and cash equivalents decreased from $310.5 million to $162.8 million due to the Ironshore Therapeutics acquisition and share repurchases.
• GAAP net income decreased for the quarter compared to the same period in the previous year.

Risks

• The company faces risks related to future opportunities and plans for its products, including uncertainty of the expected financial performance of such products.
• There are risks associated with commercializing and growing sales of products.
• The company's performance is subject to the success of competing products.
• Maintaining regulatory approval of products and securing adequate supplies of active pharmaceutical ingredient are ongoing risks.
• The company's ability to obtain reimbursement and third-party payor contracts for its products is a risk factor.
• The company's customer concentration is a risk.

Future Outlook

Collegium reaffirms its full-year 2025 guidance for product revenues, net ($735.0 to $750.0 million), adjusted operating expenses ($220.0 to $230.0 million), and adjusted EBITDA ($435.0 to $450.0 million).

Management Comments

• Vikram Karnani, President and Chief Executive Officer, stated that 2024 was a year of strong execution and that the company is poised for a new phase of growth in 2025 and beyond.
• Colleen Tupper, Chief Financial Officer, mentioned that the company delivered on its financial commitments and strategic priorities for 2024 and is in a position of financial strength.

Industry Context

Collegium's expansion into neuropsychiatry with Jornay PM positions it to capitalize on the growing ADHD market, while its established pain portfolio continues to generate significant revenue.

Comparison to Industry Standards

• Collegium's adjusted EBITDA margin of approximately 63.5% (based on 2024 Adjusted EBITDA of $401.2 million and Product Revenues of $631.4 million) is strong compared to other specialty pharmaceutical companies.
• For example, companies like Horizon Therapeutics (prior to acquisition by Amgen) and Jazz Pharmaceuticals have historically targeted adjusted EBITDA margins in the 40-50% range.
• Collegium's focus on share repurchases and debt reduction aligns with capital allocation strategies employed by other mature pharmaceutical companies generating significant cash flow, such as Amgen and AbbVie.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance, share repurchases, and strategic growth initiatives.
• Employees will benefit from the company's continued success and expansion.
• Patients will benefit from the company's commitment to improving the lives of people living with serious medical conditions.

Next Steps

• The company will focus on growing Jornay PM, maximizing its pain portfolio, and strategically deploying capital.
• Collegium will continue to expand its commercial presence in neuropsychiatry.
• The company plans to rapidly pay down debt and opportunistically repurchase shares.
• The company will host a conference call on February 27, 2025, to discuss the earnings results.

Key Dates